Fintel reports that on January 6, 2026, Wolfe Research upgraded their outlook for Immunovant (NasdaqGS:IMVT) from Peer Perform to Outperform.
Analyst Price Forecast Suggests 58.14% Upside
As of December 21, 2025, the average one-year price target for Immunovant is $39.49/share. The forecasts range from a low of $16.16 to a high of $59.85. The average price target represents an increase of 58.14% from its latest reported closing price of $24.97 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Immunovant is 61MM. The projected annual non-GAAP EPS is -1.68.
What is the Fund Sentiment?
There are 368 funds or institutions reporting positions in Immunovant. This is an increase of 1 owner(s) or 0.27% in the last quarter. Average portfolio weight of all funds dedicated to IMVT is 0.17%, an increase of 6.78%. Total shares owned by institutions decreased in the last three months by 2.06% to 100,920K shares. 
The put/call ratio of IMVT is 0.17, indicating a bullish outlook.
What are Other Shareholders Doing?
Deep Track Capital holds 9,729K shares representing 4.80% ownership of the company. In its prior filing, the firm reported owning 9,500K shares , representing an increase of 2.35%. The firm decreased its portfolio allocation in IMVT by 10.21% over the last quarter.
Armistice Capital holds 5,836K shares representing 2.88% ownership of the company. In its prior filing, the firm reported owning 5,200K shares , representing an increase of 10.90%. The firm decreased its portfolio allocation in IMVT by 19.73% over the last quarter.
Baker Bros. Advisors holds 5,458K shares representing 2.69% ownership of the company. No change in the last quarter.
T. Rowe Price Investment Management holds 5,165K shares representing 2.55% ownership of the company. In its prior filing, the firm reported owning 6,879K shares , representing a decrease of 33.19%. The firm decreased its portfolio allocation in IMVT by 26.77% over the last quarter.
FDGRX - Fidelity Growth Company Fund holds 4,693K shares representing 2.32% ownership of the company. In its prior filing, the firm reported owning 4,057K shares , representing an increase of 13.54%. The firm decreased its portfolio allocation in IMVT by 15.72% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
